Abstract
Mild neurocognitive disorder is thought to be an intermediate stage between normal age-associated cognitive changes and major neurocognitive disorder. Individuals with mild neurocognitive disorder have a faster rate of progression to major neurocognitive disorder than age-matched controls. Known risk factors for progression to major neurocognitive disorder include greater cognitive deficits at baseline, the presence of the APOE4 carrier gene, greater brain volume changes, cerebrospinal fluid changes, and the presence of neuropsychiatric symptoms. Current data indicates that the progression of mild neurocognitive disorder to major neurocognitive disorder can be delayed through the use of cognitive and physical training. Unfortunately, studies of pharmacotherapeutic agents do not indicate any benefit for cholinesterase inhibitors, the anti-inflammatory drug rofecoxib, and antioxidants in slowing the progression of mild neurocognitive disorder to major neurocognitive disorder.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC: American Psychiatric Association; 2013. p. 299–320.
Reisberg B, Ferris SH, Kluger A, et al. Mild cognitive impairment (MCI): a historical perspective. Int Psychogeriatr. 2008;20(1):18–31.
Reisberg B, Ferris SH, de Leon MJ. The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry. 1982;139(9):1136–9.
Reisberg B, Ferris SH, de Leon MJ, et al. The stage specific temporal cause of Alzheimer’s disease: functional and behavioral concomitants based upon cross-sectional and longitudinal observation. Prog Clin Biol Res. 1989;317:23–41.
Flicker C, Ferris SH, Reisberg B. Mild cognitive impairment in the elderly: predictors of dementia. Neurology. 1991;41(7):1006–9.
Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412–4.
Morris JC, Storandt M, Miller JP, et al. Mild cognitive impairment represents early-stage Alzheimer’s disease. Arch Neurol. 2001;58(3):397–405.
Petersen RC, Stevens JC, Ganguli M, et al. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56(9):1133–42.
Petersen RC. Mild cognitive impairment. Continuum. 2016;22(2 Dementia):404–18.
Petersen RC, Roberts RO, Knopman DS, et al. Prevalence of mild cognitive impairment is higher in men. The Mayo Clinic Study of Aging. Neurology. 2010;75(10):889–97.
Stephan BC, Hunter S, Harris D, et al. The neuropathological profile of mild cognitive impairment (MCI): a systematic review. Mol Psychiatry. 2012;17(11):1056–76.
Bennett DA, Schneider JA, Bienias JL, et al. Mild cognitive impairment is related to Alzheimer’s disease pathology and cerebral infarctions. Neurology. 2005;64:834–41.
Jicha GA, Parisi JE, Dickson DW, et al. Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch Neurol. 2006;63(5):674–81.
Fennema-Notestine C, McEvoy LK, Hagler DJ, et al. The Alzheimer’s disease neuroimaging initiative. Structural neuroimaging in the detection and prognosis of pre-clinical and early AD. Behav Neurol. 2009;21(1):3–12.
Koivunen J, Pirttilä T, Kemppainen N, et al. PET amyloid ligand [11C] PIB uptake and cerebrospinal fluid beta-amyloid in mild cognitive impairment. Dement Geriatr Cogn Disord. 2008;26(4):378–83.
Forsberg A, Engler H, Almkvist O, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging. 2008;29(10):1456–65.
Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56(3):303–8.
Ganguli M, Dodge HH, Shen C, DeKosky ST. Mild cognitive impairment, amnestic type. An epidemiologic study. Neurology. 2004;63(1):115–21.
Ritchie K, Artero S, Touchon J. Classification criteria for mild cognitive impairment: a population-based validation study. Neurology. 2001;56(1):37–42.
Larrieu S, Letenneur L, Orgogozo JM, et al. Incidence and outcome of mild cognitive impairment in a population-based prospective cohort. Neurology. 2002;59(10):1594–9.
Gauthier S, Reisberg B, Zaudig M, et al. International Psychogeriatric Association Expert Conference on mild cognitive impairment. Lancet. 2006;367(9518):1262–70.
Petersen RC, Negash S. Mild cognitive impairment: an overview. CNS Spectr. 2008;13(1):45–53.
Petersen RC, Caracciolo B, Brayne C, et al. Mild cognitive impairment: a concept in evolution. J Intern Med. 2014;275(3):214–28.
Jack CR, Petersen RC, YC X, et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology. 1999;52(7):1397–403.
Jack CR, Shiung MM, Weigand SD, et al. Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI. Neurology. 2005;65(8):1227–31.
Leung KK, Bartlett JW, Barnes J, et al. Cerebral atrophy in mild cognitive impairment and Alzheimer disease. Rates and acceleration. Neurology. 2013;80(7):648–54.
Herholz K. Cerebral glucose metabolism in preclinical and prodromal Alzheimer’s disease. Expert Rev Neurother. 2010;10(11):1667–73.
Ewers M, Walsh C, Trojanowski JQ, Shaw LM, et al. Prediction of conversion from mild cognitive impairment to Alzheimer’s disease dementia based upon biomarkers and neuropsychological test performance. Neurobiol Aging. 2012;33(7):1203–14.
Feldman H, Scheltens P, Scarpini E, et al. Behavioral symptoms in mild cognitive impairment. Neurology. 2004;62(7):1199–201.
Palmer K, Berger AK, Monastero R, et al. Predictors of progression from mild cognitive impairment to Alzheimer disease. Neurology. 2007;68(19):1596–602.
Butters MA, Young JB, Lopez O, et al. Pathways linking late-life depression to persistent cognitive impairment and dementia. Dialogues Clin Neurosci. 2008;10(3):345–57.
Robert PH, Berr C, Volteau M, et al. Apathy in patients with mild cognitive impairment and the risk of developing dementia of Alzheimer’s disease: a one-year follow-up study. Clin Neurol Neurosurg. 2006;108(8):733–6.
Rosenberg PB, Mielke MM, Appleby B, et al. Neuropsychiatric symptoms in MCI subtypes: the importance of executive dysfunction. Int J Geriatr Psychiatry. 2011;26(4):364–72.
Daly E, Zaitchik D, Copeland M, et al. Predicting conversion to Alzheimer’s disease using standardized clinical information. Arch Neurol. 2000;57(5):675–80.
Petersen RC. Clinical practice. Mild cognitive impairment. N Engl J Med. 2011;364(23):2227–34.
Tierney MC, Szalai JP, Snow WG, et al. A prospective study of the clinical utility of ApoE genotype in the prediction of outcome in patients with memory impairment. Neurology. 1996;46(1):149–54.
Petersen RC, Smith GE, Ivnik RJ, et al. Apolipoprotein E status as a predictor of the development of Alzheimer’s disease in memory-impaired individuals. JAMA. 1995;273(16):1274–8.
Massoud F, Belleville S, Bergman H, et al. Mild cognitive impairment and cognitive impairment, no dementia: part B, therapy. Alzheimers Dement. 2007;3(4):283–91.
Jean L, Bergeron ME, Thivierge S, Simard M. Cognitive intervention programs for individuals with mild cognitive impairment: systematic review of the literature. Am J Geriatr Psychiatry. 2010;18(4):281–96.
Lautenschlager NT, Cox KL, Flicker L, et al. Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial. JAMA. 2008;300(9):1027–37.
Li H, Li J, Li N, et al. Cognitive intervention for persons with mild cognitive impairment: a meta-analysis. Ageing Res Rev. 2011;10(2):285–96.
Reijnders J, van Heugten C, van Boxtel M. Cognitive interventions in healthy older adults and people with mild cognitive impairment: a systematic review. Ageing Res Rev. 2013;12(1):263–75.
Etgen T, Sander D, Bickel H, Förstl H. Mild cognitive impairment and dementia: the importance of modifiable risk factors. Dtsch Arztebl Int. 2011;108(44):743–50.
Raschetti R, Albanese E, Vanacore N, et al. Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials. PLoS Med. 2007;4(11):e338.
Diniz BS, Pinto JA, Gonzaga ML, et al. To treat or not to treat? A meta-analysis of the use of cholinesterase inhibitors in mild cognitive impairment for delaying progression to Alzheimer’s disease. Eur Arch Psychiatry Clin Neurosci. 2009;259(4):248–56.
Thal LJ, Ferris SH, Kirby L, et al. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology. 2005;30(6):1204–15.
Petersen RC, Thomas RG, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. New Engl J Med. 2005;352(23):2379–88.
Cooper C, Li R, Lyketsos C, Livingston G. Treatment for mild cognitive impairment: systematic review. Br J Psychiatry. 2013;203(3):255–64.
Mecocci P, Polidori MC. Antioxidant clinical trials in mild cognitive impairment and Alzheimer’s disease. Biochim Biophys Acta. 2012;1822(5):631–8.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington, VA: American Psychiatric Publishing; 2013. p. 285–320.
New Diagnostic Criteria for Alzheimer’s Disease. http://www.alz.org/research/diagnostic_criteria/. Accessed 1 Mar 2017.
Prince M, Bryce R, Albanese E, et al. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement. 2013;9(1):63–75.
Sousa RM, Ferri CP, Acosta D, et al. Contribution of chronic diseases to disability in elderly people in countries with low and middle incomes: a 10/66 Dementia Research Group population-based survey. Lancet. 2009;374(9704):1821–30.
Sousa RM, Ferri CP, Acosta D, et al. The contribution of chronic diseases to the prevalence of dependence among older people in Latin America, China and India: a 10/66 Dementia Research Group population-based survey. BMC Geriatr. 2010;10:53.
Plassman BL, Langa KM, Fisher GG, et al. Prevalence of cognitive impairment without dementia in the United States. Ann Intern Med. 2008;148(6):427–34.
Hebert LE, Weuve J, Scherr PA, et al. Alzheimer disease in the United States (2010–2050) estimated using the 2010 census. Neurology. 2013;80(19):1778–83.
Hugo J, Ganguli M. Dementia and cognitive impairment: epidemiology, diagnosis, and treatment. Clin Geriatr Med. 2014;30(3):421–42.
Fiest KM, Jetté N, Roberts JI, et al. The Prevalence and Incidence of Dementia: a Systematic Review and Meta-analysis. Can J Neurol Sci. 2016;43:S3–S50.
Anstey KJ, Eramudugolla R, Hosking DE, et al. Bridging the Translation Gap: from Dementia Risk Assessment to Advice on Risk Reduction. J Prev Alzheimers Dis. 2015;2:189–98.
Morris MC, Tangney CC, Wang Y, et al. MIND diet slows cognitive decline with aging. Alzheimers Dement. 2015;11(9):1015–22.
Abete P, Della-Morte D, Gargiulo G, et al. Cognitive impairment and cardiovascular diseases in the elderly. A heart-brain continuum hypothesis. Ageing Res Rev. 2014;18:41–52.
Billioti de Gage S, Pariente A, Bégaud BI. there really a link between benzodiazepine use and the risk of dementia? Expert Opin Drug Saf. 2015;14(5):733–47.
Gray SL, Anderson ML, Dublin S, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 2015;175(3):401–7.
Tannenbaum C, Paquette A, Hilmer S, et al. A systematic review of amnestic and non-amnestic mild cognitive impairment induced by anticholinergic, antihistamine, GABAergic and opioid drugs. Drugs Aging. 2012;29(8):639–58.
Xu W, Tan L, Wang HF, et al. Meta-analysis of modifiable risk factors for Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 2015;86(12):1299–306.
Henderson VW. Action of estrogens in the aging brain: dementia and cognitive aging. Biochim Biophys Acta. 2010;1800(10):1077–83.
Zhou B, Teramukai S, Fukushima M. Prevention and treatment of dementia or Alzheimer’s disease by statins: a meta-analysis. Dement Geriatr Cogn Disord. 2007;23(3):194–201.
McGuinness B, Todd S, Passmore P, Bullock R. Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. Cochrane Database Syst Rev. 2009;7(4):CD004034.
Imbimbo BP. An update on the efficacy of non-steroidal anti-inflammatory drugs in Alzheimer’s disease. Expert Opin Investig Drugs. 2009;18(8):1147–68.
Dá Mesquita S, Ferreira AC, Sousa JC, et al. Insights on the pathophysiology of Alzheimer’s disease: the crosstalk between amyloid pathology, neuroinflammation and the peripheral immune system. Neurosci Biobehav Rev. 2016;68:547–62.
Scheltens P, Blennow K, Breteler MM, et al. Alzheimer’s disease. Lancet. 2016;388(10043):505–1.
O'Brien JT, Thomas A. Vascular dementia. Lancet. 2015;386(10004):1698–706.
Iadecola C. The pathobiology of vascular dementia. Neuron. 2013;80(4):844–66.
Bang J, Spina S, Miller BL. Frontotemporal dementia. Lancet. 2015;386(10004):1672–82.
Perry DC, Miller BL. Frontotemporal dementia. Semin Neurol. 2013;33(4):336–41.
Mayo MC, Bordelon Y. Dementia with Lewy bodies. Semin Neurol. 2014;34(2):182–8.
Walker Z, Possin KL, Boeve BF, et al. Lewy body dementias. Lancet. 2015;386(10004):1683–97.
Jing W, Willis R, Feng Z. Factors influencing quality of life of elderly people with dementia and care implications: a systematic review. Arch Gerontol Geriatr. 2016;66:23–41.
Kua EH, Ho E, Tan HH, et al. The natural history of dementia. Psychogeriatrics. 2014;14(3):196–201.
Jellinger KA, Wenning GK, Seppi K. Predictors of survival in dementia with lewy bodies and Parkinson dementia. Neurodegener Dis. 2007;4(6):428–30.
Darrow MDA. practical approach to dementia in the outpatient primary care setting. Prim Care. 2015;42(2):195–204.
Tsoi KK, Chan JY, Hirai HW, et al. Cognitive tests to detect dementia: a systematic review and meta-analysis. JAMA Intern Med. 2015;175(9):1450–8.
Feliciano L, Horning SM, Klebe KJ, et al. Utility of the SLUMS as a cognitive screening tool among a nonveteran sample of older adults. Am J Geriatr Psychiatry. 2013;21(7):623–30.
Feldman HH, Jacova C, Robillard A, et al. Diagnosis and treatment of dementia: 2. Diagnosis. CMAJ. 2008;178(7):825–36.
Narayanan L, Murray AD. What can imaging tell us about cognitive impairment and dementia? World J Radiol. 2016;8(3):240–54.
Burrell JR, Piguet O. Lifting the veil: how to use clinical neuropsychology to assess dementia. J Neurol Neurosurg Psychiatry. 2015;86(11):1216–24.
Sancesario GM, Bernardini S. How many biomarkers to discriminate neurodegenerative dementia? Crit Rev. Clin Lab Sci. 2015;52(6):314–26.
Downing LJ, Caprio TV, Lyness JM. Geriatric psychiatry review: differential diagnosis and treatment of the 3 D’s - delirium, dementia, and depression. Curr Psychiatry Rep. 2013;15(16):365.
Shatenstein B, Barberger-Gateau P, Mecocci P. Prevention of age-related cognitive decline: which strategies, when, and for whom? J Alzheimers Dis. 2015;48(1):35–53.
Cheng ST. Cognitive reserve and the prevention of dementia: the role of physical and cognitive activities. Curr Psychiatry Rep. 2016;18(9):85.
Norton S, Matthews FE, Barnes DE, et al. Potential for primary prevention of Alzheimer’s disease: an analysis of population-based data. Lancet Neurol. 2014;13(8):788–94.
Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer’s disease prevalence. Lancet Neurol. 2011;10(9):819–28.
Anand R, Gill KD, Mahdi AA. Therapeutics of Alzheimer’s disease: past, present and future. Neuropharmacology. 2014;76:27–50.
Tan CC, Yu JT, Wang HF, et al. Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer’s disease: a systematic review and meta-analysis. Alzheimer Dis. 2014;41(2):615–31.
Tsoi KK, Chan JY, Leung NW, et al. Combination therapy showed limited superiority over monotherapy for Alzheimer disease: a meta-analysis of 14 randomized trials. J Am Med Dir Assoc. 2016;17(9):863.e1–8.
Atri A, Hendrix SB, Pejović V, et al. Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimer’s dementia: a pooled area under the curve analysis. Alzheimers Res Ther. 2015;7(1):28.
Kavirajan H, Schneider LS. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet Neurol. 2007;6(9):782–92.
Nardell M, Tampi RR. Pharmacological treatments for frontotemporal dementias: a systematic review of randomized controlled trials. Am J Alzheimers Dis Other Demen. 2014;29(2):123–32.
Stinton C, McKeith I, Taylor JP, et al. Pharmacological Management of Lewy Body Dementia: a Systematic Review and Meta-Analysis. Am J Psychiatry. 2015;172(8):731–42.
Sarva H, Henchcliffe C. Evidence for the use of pimavanserin in the treatment of Parkinson’s disease psychosis. Ther Adv Neurol Disord. 2016;9(6):462–73.
Bharucha AJ, Rosen J, Mulsant BH, et al. Assessment of behavioral and psychological symptoms of dementia. CNS Spectr. 2002;7(11):797–802.
Lyketsos CG, Steinberg M, Tschanz JT, et al. Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am J Psychiatry. 2000;157(5):708–14.
Margallo-Lana M, Swann A, O'Brien J, et al. Prevalence and pharmacological management of behavioural and psychological symptoms amongst dementia sufferers living in care environments. Int J Geriatr Psychiatry. 2001;16(1):39–44.
Jost BC, Grossberg GT. The evolution of psychiatric symptoms in Alzheimer’s disease: a natural history study. J Am Geriatr Soc. 1996;44(9):1078–81.
Lyketsos CG, Olin J. Depression in Alzheimer’s disease: overview and treatment. Biol Psychiatry. 2002;52(3):243–52.
Burns A, Jacoby R, Levy R. Psychiatric phenomena in Alzheimer’s disease. I: disorders of thought content. Br J Psychiatry. 1990;157:72–6, 92–4
Devanand DP, Jacobs DM, Tang MX, et al. The course of psychopathologic features in mild to moderate Alzheimer disease. Arch Gen Psychiatry. 1997;54:257–63.
Mega MS, Cummings JL, Fiorello T, et al. The spectrum of behavioral changes in Alzheimer’s disease. Neurology. 1996;46:130–5.
Lee HB, Lyketsos CG. Depression in Alzheimer’s disease: heterogeneity and related issues. Biol Psychiatry. 2003;54(3):353–62.
Olin JT, Katz IR, Meyers BS, et al. Provisional diagnostic criteria for depression of Alzheimer disease: rationale and background. Am J Geriatr Psychiatry. 2002;10(2):129–41.
Pearlson GD, Ross CA, Lohr WD, et al. Association between family history of affective disorder and the depressive syndrome of Alzheimer’s disease. Am J Psychiatry. 1990;37:452–6.
Rose KM, Lorenz R. Sleep disturbances in dementia. J Gerontol Nurs. 2010;36(5):9.
White H, Pieper C, Schmader K. The association of weight change in Alzheimer’s disease with severity of disease and mortality: a longitudinal analysis. J Am Geriatr Soc. 1998;46(10):1223–7.
Black B, Muralee S, Tampi RR. Inappropriate sexual behaviors in dementia. J Geriatr Psychiatry Neurol. 2005;18(3):155–62.
Zubenko GS, Moossy J, Martinez J, et al. Neuropathologic and neurochemical correlates of psychosis in primary dementia. Arch Neurol. 1991;48:619–24.
Victoroff J, Zarow C, Mack WJ, et al. Physical aggression is associated with preservation of substantia nigra pars compacta in Alzheimer’s disease. Arch Neurol. 1996;53:428–34.
Farber NB, Rubin EH, Newcomer JW, et al. Increased neocortical neurofibrillary tangle density in subjects with Alzheimer disease and psychosis. Arch Gen Psychiatry. 2000;57(12):1165–73.
Tekin S, Mega MS, Masterman DM, et al. Orbitofrontal and anterior cingulate cortex neurofibrillary tangle burden is associated with agitation in Alzheimer disease. Ann Neurol. 2001;49(3):355–61.
Forstl H, Besthorn C, Burns A, et al. Delusional misidentification in Alzheimer’s disease: a summary of clinical and biological aspects. Psychopathology. 1994;27(3–5):194–9.
Kotrla KJ, Chacko RC, Harper RG, et al. Clinical variables associated with psychosis in Alzheimer’s disease. Am J Psychiatry. 1995;152(9):1377–9.
Starkstein SE, Vazquez S, Petracca G, et al. A SPECT study of delusions in Alzheimer’s disease. Neurology. 1994;44(11):2055–9.
Mentis MJ, Weinstein EA, Horwitz B, et al. Abnormal brain glucose metabolism in the delusional misidentification syndromes: a positron emission tomography study in Alzheimer disease. Biol Psychiatry. 1995;38(7):438–49.
Sultzer DL, Mahler ME, Mandelkern MA, et al. The relationship between psychiatric symptoms and regional cortical metabolism in Alzheimer’s disease. J Neuropsychiatry Clin Neurosci. 1995;7(4):476–84.
Hirono N, Mori E, Ishii K, et al. Alteration of regional cerebral glucose utilization with delusions in Alzheimer’s disease. J Neuropsychiatry Clin Neurosci. 1998;10(4):433–9.
Cummings JL, Back C. The cholinergic hypothesis of neuropsychiatric symptoms in Alzheimer’s disease. Am J Geriatr Psychiatry. 1998;6(2 Suppl 1):S64–78.
Strauss ME, Ogrocki PK. Confirmation of an association between family history of affective disorder and the depressive syndrome in Alzheimer’s disease. Am J Psychiatry. 1996;153(10):1340–2.
Lyketsos CG, Tune LE, Pearlson G, et al. Major depression in Alzheimer’s disease. An interaction between gender and family history. Psychosomatics. 1996;37(4):380–4.
Bacanu SA, Devlin B, Chowdari KV, et al. Heritability of psychosis in Alzheimer disease. Am J Geriatr Psychiatry. 2005;13(7):624–7.
Ballard C, Massey H, Lamb H, et al. Apolipoprotein E: non-cognitive symptoms and cognitive decline in late onset Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 1997;63(2):273–4.
Cacabelos R, Rodríguez B, Carrera C, et al. APOE-related frequency of cognitive and noncognitive symptoms in dementia. Methods Find Exp Clin Pharmacol. 1996;18(10):693–706.
Holmes C, Arranz MJ, Powell JF, et al. 5-HT2A and 5-HT2C receptor polymorphisms and psychopathology in late onset Alzheimer’s disease. Hum Mol Genet. 1998;7(9):1507–9.
Sukonick DL, Pollock BG, Sweet RA, et al. The 5-HTTPR*S/*L polymorphism and aggressive behavior in Alzheimer disease. Arch Neurol. 2001;58(9):1425–8.
Sweet RA, Nimgaonkar VL, Kamboh MI, et al. Dopamine receptor genetic variation, psychosis, and aggression in Alzheimer disease. Arch Neurol. 1998;55(10):1335–40.
Holmes C, Smith H, Ganderton R, et al. Psychosis and aggression in Alzheimer’s disease: the effect of dopamine receptor gene variation. J Neurol Neurosurg Psychiatry. 2001;71(6):777–9.
Meins W, Frey A, Thiesemann R. Premorbid personality traits in Alzheimer’s disease: do they predispose to noncognitive behavioral symptoms? Int Psychogeriatr. 1998;10(4):369–78.
Chatterjee A, Strauss ME, Smyth KA, et al. Personality changes in Alzheimer’s disease. Arch Neurol. 1992;49(5):486–91.
Lawlor B. Managing behavioural and psychological symptoms of dementia. Br J Psychiatry. 2002;181:463–5.
Coen RF, Swanwick GR, O'Boyle CA, et al. Behaviour disturbance and other predictors of carer burden in Alzheimer’s disease. Int J Geriatr Psychiatry. 1997;12(3):331–6.
Kaufer DI, Cummings JL, Christine D, et al. Assessing the impact of neuropsychiatric symptoms in Alzheimer’s disease: the Neuropsychiatric Inventory Caregiver Distress Scale. J Am Geriatr Soc. 1998;46(2):210–5.
O'Donnell BF, Drachman DA, Barnes HJ, et al. Incontinence and troublesome behaviors predict institutionalization in dementia. J Geriatr Psychiatry Neurol. 1992;5(1):45–52.
Steele C, Rovner B, Chase GA, et al. Psychiatric symptoms and nursing home placement of patients with Alzheimer’s disease. Am J Psychiatry. 1990;147(8):1049–51.
Stern Y, Albert M, Brandt J, et al. Utility of extrapyramidal signs and psychosis as predictors of cognitive and functional decline, nursing home admission, and death in Alzheimer’s disease: prospective analyses from the Predictors Study. Neurology. 1994;44:2300–7.
Stern Y, Mayeux R, Sano M, et al. Predictors of disease course in patients with probable Alzheimer’s disease. Neurology. 1987;37:1649–53.
Beeri MS, Werner P, Davidson M, et al. The cost of behavioral and psychological symptoms of dementia (BPSD) in community dwelling Alzheimer’s disease patients. Int J Geriatr Psychiatry. 2002;17(5):403–8.
Murman DL, Chen Q, Powell MC, et al. The incremental direct costs associated with behavioral symptoms in AD. Neurology. 2002;59(11):1721–9.
Robert PH, Verhey FR, Byrne EJ, et al. Grouping for behavioral and psychological symptoms in dementia: clinical and biological aspects. Consensus paper of the European Alzheimer disease consortium. Eur Psychiatry. 2005;20(7):490–6.
Jeon YH, Sansoni J, Low LF, et al. Recommended measures for the assessment of behavioral disturbances associated with dementia. Am J Geriatr Psychiatry. 2011;19(5):403–15.
Lanari A, Amenta F, Silvestrelli G, et al. Neurotransmitter deficits in behavioural and psychological symptoms of Alzheimer’s disease. Mech Ageing Dev. 2006;127(2):158–65.
Livingston G, Johnston K, Katona C, et al. Old age task force of the world federation of biological psychiatry. Systematic review of psychological approaches to the management of neuropsychiatric symptoms of dementia. Am J Psychiatry. 2005;162(11):1996–2021.
Brodaty H, Arasaratnam C. Meta-analysis of nonpharmacological interventions for neuropsychiatric symptoms of dementia. Am J Psychiatry. 2012;169(9):946–53.
Seitz DP, Brisbin S, Herrmann N, et al. Efficacy and feasibility of nonpharmacological interventions for neuropsychiatric symptoms of dementia in long term care: a systematic review. J Am Med Dir Assoc. 2012;13(6):503–6.
Ballard CG, Waite J, Birks J. Atypical antipsychotics for aggression and psychosis in Alzheimer’s disease. Cochrane Database Syst Rev. 2009;4:1–128.
Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry. 2006;14(3):191–210.
Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness and safety of atypical antipsychotic drugs in patients with Alzheimer’s disease. N Engl J Med. 2006;355(15):1525–38.
Mittal V, Kurup L, Williamson D, et al. Review: risk of cerebrovascular adverse events and death in elderly patients with dementia when treated with antipsychotic medications: a literature review of evidence. Am J Alzheimers Dis Other Demen. 2011;26(1):10–28.
Herrmann N, Lanctot KL. Do atypical antipsychotics cause stroke? CNS Drugs. 2005;19(2):91–103.
Gill SS, Rochon PA, Herrmann N, et al. Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. BMJ. 2005;330(7489):445.
Liperoti R, Gambassi G, Lapane KL, et al. Cerebrovascular events among elderly nursing home patients treated with conventional or atypical antipsychotics. J Clin Psychiatry. 2005;66(9):1090–6.
Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294(15):1934–43.
Wang PS, Schneeweiss S, Avorn J, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med. 2005;353(22):2335–41.
Reus V, Fochtmann L, Eyler A, et al. The American psychiatric association practice guideline on the use of Antipsychotics to treat agitation or Psychosis in patients with dementia. Am J Psychiatry. 2016;173(5):543–6.
Seitz DP, Adunuri N, Gill SS, et al. Antidepressants for agitation and psychosis in dementia. Cochrane Database Syst Rev. 2011;16(2):CD008191.
Henry G, Williamson D, Tampi RR. Efficacy and tolerability of antidepressants in the treatment of behavioral and psychological symptoms of dementia, a literature review of evidence. Am J Alzheimers Dis Other Demen. 2011;26(3):169–83.
Lonergan ET, Cameron M, Luxenberg J. Valproic acid for agitation in dementia. Cochrane Database Syst Rev. 2004;2:CD003945.
Konovalov S, Muralee S, Tampi RR. Anticonvulsants for the treatment of behavioral and psychological symptoms of dementia: a literature review. Int Psychogeriatr. 2008;20(2):293–308.
Trinh NH, Hoblyn J, Mohanty S, et al. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA. 2003;289:210–6.
Maidment ID, Fox CG, Boustani M, et al. Efficacy of memantine on behavioral and psychological symptoms related to dementia: a systematic meta-analysis. Ann Pharmacother. 2008;42(1):32–8.
Tampi RR, Tampi DJ. Efficacy and tolerability of benzodiazepines for the treatment of behavioral and psychological symptoms of dementia: a systematic review of randomized controlled trials. Am J Alzheimers Dis Other Demen. 2014;29(7):565–74.
Jansen S, Forbes D, Duncan V, et al. Melatonin for cognitive impairment. Cochrane Database Syst Rev. 2006;25(1):CD003802.
Desk Reference to the Diagnostic Criteria from DSM-5. Washington DC: American Psychiatric Association. 2013. P. 292–8.
Saxena S, Lawley D. Delirium in the elderly: a clinical review. Postgrad Med J. 2009;85(1006):405–13.
Fong TG, Tulebaev SR, Inouye SK. Delirium in elderly adults: diagnosis, prevention and treatment. Nat. Rev Neurol. 2009;5(4):210–20.
Khan BA, Zawahiri M, Campbell NL, et al. Delirium in hospitalized patients: implications of current evidence on clinical practice and future avenues for research-a systematic evidence review. J Hosp Med. 2012;7(7):580–9.
Miller MO. Evaluation and management of delirium in hospitalized older patients. Am Fam Physician. 2008;78(11):1265–70.
Inouye SK. Predisposing and precipitating factors for delirium in hospitalized older patients. Dement Geriatr Cogn Disord. 1999;10(5):393–400.
Inouye SK, Charpentier PA. Precipitating factors for delirium in hospitalized elderly persons. Predictive model and interrelationship with baseline vulnerability. JAMA. 1996;275(11):852–7.
Laurila JV, Laakkonen ML, Tilvis RS, et al. Predisposing and precipitating factors for delirium in a frail geriatric population. J Psychosom Res. 2008;65(3):249–54.
Siddiqi N, House AO, Holmes JD. Occurrence and outcome of delirium in medical in-patients: a systematic literature review. Age Ageing. 2006;35(4):350–64.
Rockwood K, Cosway S, Carver D, et al. The risk of dementia and death after delirium. Age Ageing. 1999;28(6):551–6.
Leslie DL, Marcantonio ER, Zhang Y, et al. One-year health care costs associated with delirium in the elderly population. Arch Intern Med. 2008;168(1):27–32.
Young J, Inouye SK. Delirium in older people. BMJ. 2007;334(7598):842–6.
Wong CL, Holroyd-Leduc J, Simel DL, et al. Does this patients have delirium?: value of bedside instruments. JAMA. 2010;304(7):779–86.
Cole MG. Delirium in elderly patients. Am J Geriatr Psychiatry. 2004;12(1):7–21.
Luetz A, Heymann A, Radtke FM, et al. Different assessment tools for intensive care unit delirium: which score to use? Crit Care Med. 2010;38(2):409–18.
Adamis D, Sharma N, Whelan PJ, et al. Delirium scales: a review of current evidence. Aging Ment Health. 2010;14(5):543–55.
Zou Y, Cole MG, Primeau FJ, et al. Detection and diagnosis of delirium in the elderly: psychiatric diagnosis, confusion assessment method, or consensus diagnosis? Int Psychogeriatr. 1998;10(3):303–8.
Inouye SK, Bogardus ST Jr, Charpentier PA, Leo-Summers L, et al. A multicomponent intervention to prevent delirium in hospitalized older patients. N Engl J Med. 1999;340(9):669–76.
Rizzo JA, Bogardus ST, Leo-Summers L, et al. Multicomponent targeted intervention to prevent delirium in hospitalized older patients: what is the economic value? Med Care. 2001;39:740–52.
Leslie DL, Zhang Y, Bogardus ST, et al. Consequences of preventing delirium in hospitalized older adults on nursing home costs. J Am Geriatr Soc. 2005;53(3):405–9.
Marcantonio ER, Flacker JM, Wright RJ, et al. Reducing delirium after hip fracture: a randomized trial. J Am Geriatr Soc. 2001;49(5):516–22.
Caplan GA, Coconis J, Board N, et al. Does home treatment affect delirium? A randomised controlled trial of rehabilitation of elderly and care at home or usual treatment (The REACH-OUT trial). Age Ageing. 2006;35(1):53–60.
Milisen K, Lemiengre J, Braes T, et al. Multicomponent intervention strategies for managing delirium in hospitalized older people: systematic review. J Adv Nurs. 2005;52(1):79–90.
Clegg A, Siddiqi N, Heaven A, Young J, et al. Interventions for preventing delirium in older people in institutional long-term care. Cochrane Database Syst Rev. 2014;1:CD009537.
Martinez F, Tobar C, Hill N. Preventing delirium: should non-pharmacological, multicomponent interventions be used? A systematic review and meta-analysis of the literature. Age Ageing. 2015;44(2):196–204.
Teslyar P, Stock VM, Wilk CM, et al. Prophylaxis with antipsychotic medication reduces the risk of post-operative delirium in elderly patients: a meta-analysis. Psychosomatics. 2013;54(2):124–31.
Fok MC, Sepehry AA, Frisch L, et al. Do antipsychotics prevent postoperative delirium? A systematic review and meta-analysis. Int J Geriatr Psychiatry. 2015;30(4):333–44.
Cole MG, Fenton FR, Engelsmann F, et al. Effectiveness of geriatric psychiatry consultation in an acute care hospital: a randomized clinical trial. J Am Geriatr Soc. 1991;39(12):1183–8.
Cole MG, Primeau FJ, Bailey RF, et al. Systematic intervention for elderly inpatients with delirium: a randomized trial. CMAJ. 1994;151(7):965–70.
Milisen K, Foreman MD, Abraham IL, et al. A nurse-led interdisciplinary intervention program for delirium in elderly hip-fracture patients. J Am Geriatr Soc. 2001;49(5):523–32.
Cole MG, McCusker J, Bellavance F, et al. Systematic detection and multidisciplinary care of delirium in older medical inpatients: a randomized trial. CMAJ. 2002;167(7):753–9.
Lonergan E, Britton AM, Luxenberg J, et al. Antipsychotics for delirium. Cochrane Database Syst Rev. 2007;2:CD005594.
Ozbolt LB, Paniagua MA, Kaiser RM. Atypical antipsychotics for the treatment of delirious elders. J Am Med Dir Assoc. 2008;9(1):18–28.
Liptzin B, Laki A, Garb JL, et al. Donepezil in the prevention and treatment of post-surgical delirium. Am J Geriatr Psychiatry. 2005;13(12):1100–6.
Sampson EL, Raven PR, Ndhlovu PN, et al. A randomized, double-blind, placebo-controlled trial of donepezil hydrochloride (Aricept) for reducing the incidence of postoperative delirium after elective total hip replacement. Int J Geriatr Psychiatry. 2007;22(4):343–9.
Gamberini M, Bolliger D, Lurati Buse GA, et al. Rivastigmine for the prevention of postoperative delirium in elderly patients undergoing elective cardiac surgery-a randomized controlled trial. Crit Care Med. 2009;37(5):1762–8.
Overshott R, Vernon M, Morris J, et al. Rivastigmine in the treatment of delirium in older people: a pilot study. Int Psychogeriatr. 2010;22(5):812–8.
Chakraborti D, Tampi DJ, Tampi RR. Melatonin and Melatonin Agonist for Delirium in the Elderly Patients. Am J Alzheimers Dis Other Demen. 2015;30(2):119–29.
Lonergan E, Luxenberg J, Areosa SA. Benzodiazepines for delirium. Cochrane Database Syst Rev. 2009;4:CD006379.
Treatment of Patients with Delirium. http://www.psychiatryonline.com/pracguidetopic_2.aspx. Accessed 5 Jun 2017.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Tampi, R.R., Tampi, D.J., Canio, W.C., Alag, P., Dasarathy, D., Dey, J.P. (2018). Neurocognitive Disorders. In: Tampi, R., Tampi, D., Boyle, L. (eds) Psychiatric Disorders Late in Life. Springer, Cham. https://doi.org/10.1007/978-3-319-73078-3_16
Download citation
DOI: https://doi.org/10.1007/978-3-319-73078-3_16
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-73076-9
Online ISBN: 978-3-319-73078-3
eBook Packages: MedicineMedicine (R0)